Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02112565CT.gov RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer Of Unknown Primary Site
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| COH-29 (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Amifostine | M.D. Anderson Cancer Center | P4 | BBB |
| Nepenthe | M.D. Anderson Cancer Center | P4 | BBB |
| Dexasone | Alliance for Clinical Trials in Oncology | P3 | BBB |
| Etoposide | University of California, Davis | P2/3 | BBB |
| Nogitecan | National Cancer Institute (NCI) | P2 | BBB |
| Docetaxel | University of Wisconsin, Madison | P2 | BBB |
| Melphalan | City of Hope Medical Center | P2/3 | BBB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BBB |
+42 more in the Cancer Of Unknown Primary Site cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. COH-29 in Cancer Of Unknown Primary Site. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/coh-29-cancer-of-unknown-primary-site
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →